Market Madness Showdown: AbbVie vs. GlaxoSmithKline

In honor of March Madness, The Motley Fool's health-care team assembled their own bracket consisting of the 16 largest and best pharmaceutical and biotech stocks on the market. The series gets under way with a tough matchup between AbbVie  (NYSE: ABBV  ) , Abbott's recently spun-off pharmaceutical division, and Big Pharma giant GlaxoSmithKline (NYSE: GSK  ) . To learn the bull and bear cases for each stock -- and to see which stock will move on to the Elite Eight -- watch the following video.

In the pharma business, great success comes with a caveat. AbbVie is a perfect example, as investors in the new company are left wondering what the future holds once the company's golden goose, Humira, is cooked. The Fool's brand-new premium report on the company answers the high-profile questions that AbbVie investors are asking. Simply click here now to claim your copy today.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2338174, ~/Articles/ArticleHandler.aspx, 7/24/2014 4:41:51 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement